跳转至内容
Merck
CN

890850C

Avanti

18:1 DAP

Avanti Research™ - A Croda Brand

别名:

1,2-二油酰-3-二甲基铵-丙烷(DODAP)

登录 查看组织和合同定价。

选择尺寸

关于此项目

经验公式（希尔记法）:
C41H77NO4
化学文摘社编号:
127512-29-2
分子量:
648.05
MDL number:
MFCD01321074
UNSPSC Code:
12352211
NACRES:
NA.25

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

18:1 DAP, Avanti Research™ - A Croda Brand 890850C

SMILES string

[H]C(CN(C)C)(OC(CCCCCCC/C=C\CCCCCCCC)=O)COC(CCCCCCC/C=C\CCCCCCCC)=O

InChI

1S/C41H77NO4/c1-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-35-40(43)45-38-39(37-42(3)4)46-41(44)36-34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-2/h19-22,39H,5-18,23-38H2,1-4H3/b21-19-,22-20-

InChI key

NYDLOCKCVISJKK-WRBBJXAJSA-N

assay

>99% (TLC)

form

liquid

packaging

pkg of 1 × 2.5 mL (890850C-25mg)
pkg of 2 × 4 mL (890850C-200mg)

manufacturer/tradename

Avanti Research™ - A Croda Brand 890850C

concentration

10 mg/mL (890850C-25mg)
25 mg/mL (890850C-200mg)

lipid type

transfection
cationic lipids

shipped in

dry ice

storage temp.

−20°C

相关类别

Application

18:1 DAP适用于：
  • 作为脂质双分子层组分
  • 制备稳定的核酸脂质囊泡
  • 含反义寡脱氧核糖核苷酸（ODN）的叶酸（FA）靶向脂质体和非靶向脂质体的制备和理化特性表征

General description

18:1 DAP是一种阳离子脂质。作为pH敏感性转染试剂，可用于制备阳离子脂质体。

Packaging

5 mL透明玻璃密封安瓿(890850C-200mg)
5 mL透明玻璃密封安瓿(890850C-25mg)

Legal Information

Avanti Research is a trademark of Avanti Polar Lipids, LLC

pictograms

Skull and crossbonesHealth hazard
GHS06,GHS08

signalword

Danger

Hazard Classifications

Acute Tox. 3 Inhalation - Acute Tox. 4 Oral - Carc. 2 - Eye Irrit. 2 - Repr. 2 - Skin Irrit. 2 - STOT RE 1 Oral - STOT SE 3

target_organs

Liver,Kidney, Respiratory system

存储类别

6.1D - Non-combustible acute toxic Cat.3 / toxic hazardous materials or hazardous materials causing chronic effects

wgk

WGK 3

flash_point_f

does not flash

flash_point_c

does not flash

法规信息

易制毒化学品（2类）
危险化学品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系 客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Preparation and in-vitro evaluation of an antisense-containing cationic liposome against non-small cell lung cancer: a comparative preparation study
Saffari M, et al.
Iranian Journal of Pharmaceutical Research : IJPR, 12, 3-3 (2013)
Transferrin-conjugated SNALPs encapsulating 2?-O-methylated miR-34a for the treatment of multiple myeloma
Scognamiglio I, et al.
BioMed Research International, 2014 (2014)
Nonequilibrium adhesion patterns at lipid bilayer junctions
Parthasarathy R, et al.
The Journal of Physical Chemistry B, 108(2), 649-657 (2004)
Qiang Cheng et al.
Nature nanotechnology, 15(4), 313-320 (2020-04-07)
CRISPR-Cas gene editing and messenger RNA-based protein replacement therapy hold tremendous potential to effectively treat disease-causing mutations with diverse cellular origin. However, it is currently impossible to rationally design nanoparticles that selectively target specific tissues. Here, we report a strategy

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持